Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Investing Activities (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Cash from Investing Activities for 6 consecutive years, with $35.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 470.71% year-over-year to $35.5 million, compared with a TTM value of -$311.7 million through Sep 2025, down 2405.42%, and an annual FY2024 reading of -$394.6 million, down 3491.41% over the prior year.
  • Cash from Investing Activities was $35.5 million for Q3 2025 at Autolus Therapeutics, down from $95.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $95.9 million in Q2 2025 and bottomed at -$383.6 million in Q4 2024.
  • Average Cash from Investing Activities over 4 years is -$27.9 million, with a median of -$1.5 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities plummeted 25870.82% in 2024, then soared 11504.88% in 2025.
  • Year by year, Cash from Investing Activities stood at -$633000.0 in 2022, then crashed by 133.33% to -$1.5 million in 2023, then tumbled by 25870.82% to -$383.6 million in 2024, then soared by 109.27% to $35.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for AUTL at $35.5 million in Q3 2025, $95.9 million in Q2 2025, and -$59.5 million in Q1 2025.